Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14431503 | 0.86 | SIGMAR1 (0.60) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL13185550 | 0.81 | SIGMAR1 (0.53) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL5208400 | 0.78 | SIGMAR1 (0.55) | SIGMAR1ABCB1PTGIRPTGDR | |
| Hydrochloric Acid SCHEMBL11079501 | 0.78 | SIGMAR1 (0.51) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL17187820 | 0.77 | SIGMAR1 (0.53) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL31332008 | 0.77 | SIGMAR1 (0.53) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL5211925 | 0.77 | SIGMAR1 (0.51) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL4780350 | 0.75 | ABCB1 (0.84) | SIGMAR1ABCB1 | |
| SCHEMBL14291716 | 0.75 | ABCB1 (1.00) | SIGMAR1ABCB1 | |
| SCHEMBL9164109 | 0.75 | SIGMAR1 (1.00) | SIGMAR1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008017588-A1 | VERAPAMIL ANALOGUES WITH INHIBITION ACTIVITY ON ABC (ATP BINDING CASSETTE) CELL EXTRUSION PUMPS | ISTITUTO TUMORI 'Giovanni Paolo II' IRCCS - Laboratorio di Oncologia Sperimentale Clinica (IT) | 2008-02-14 | — | — | WO | disclosed |
| EP-1354879-B1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1354879-B1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-12-21 | — | — | US | disclosed |
| EP-1726586-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1354879-A1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | SREBF1, NR1H2, NR1H3 | SIGMAR1 1017/4885ABCB1 561/4885PTGIR 376/4885 |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | SREBF1, NR1H2, NR1H3 | SIGMAR1 542/4885ABCB1 225/4885PTGIR 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.